The disease burden of influenza beyond respiratory illness
- PMID: 33041103
- PMCID: PMC7545338
- DOI: 10.1016/j.vaccine.2020.09.048
The disease burden of influenza beyond respiratory illness
Abstract
Although influenza is primarily considered a respiratory infection and causes significant respiratory mortality, evidence suggests that influenza has an additional burden due to broader consequences of the illness. Some of these broader consequences include cardiovascular events, exacerbations of chronic underlying conditions, increased susceptibility to secondary bacterial infections, functional decline, and poor pregnancy outcomes, all of which may lead to an increased risk for hospitalization and death. Although it is methodologically difficult to measure these impacts, epidemiological and interventional study designs have evolved over recent decades to better take them into account. Recognizing these broader consequences of influenza virus infection is essential to determine the full burden of influenza among different subpopulations and the value of preventive approaches. In this review, we outline the main influenza complications and societal impacts beyond the classical respiratory symptoms of the disease.
Keywords: Burden of disease; Cardiovascular events; Comorbidity; Complications; Influenza virus; Vaccination.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JN, SSC, SIS, and BTS are employees of Sanofi Pasteur. AEM has received honoraria for lectures or advisory boards from Sanofi Pasteur, Stendhal Pharma, Roche, and Pfizer. JEM has received honoraria for participation in advisory boards or lectures and related travel support from Sanofi, and participation in data monitoring boards or advisory boards for GSK, Pfizer, Merck, and Medicago. MCN has received honoraria for lectures or advisory boards from Sanofi Pasteur and Pfizer, and research grants from MedImmune. TW has received honoraria for lectures or advisory boards from MSD, Sanofi Pasteur, and Seqirus. HY has received investigator-initiated research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Roche (Shanghai).
Figures
Similar articles
-
Influenza and respiratory syncytial virus in the elderly.Expert Rev Vaccines. 2008 Mar;7(2):249-58. doi: 10.1586/14760584.7.2.249. Expert Rev Vaccines. 2008. PMID: 18324893 Review.
-
Hospital and economic burden of influenza-like illness and lower respiratory tract infection in adults ≥50 years-old.BMC Health Serv Res. 2019 Aug 19;19(1):585. doi: 10.1186/s12913-019-4412-7. BMC Health Serv Res. 2019. PMID: 31426795 Free PMC article.
-
Antiviral drugs in influenza: an adjunct to vaccination in some situations.Prescrire Int. 2006 Feb;15(81):21-30. Prescrire Int. 2006. PMID: 16548114
-
Influenza in Singapore: assessing the burden of illness in the community.Ann Acad Med Singap. 2002 Mar;31(2):182-8. Ann Acad Med Singap. 2002. PMID: 11957555
-
Burden and disease pathogenesis of influenza and other respiratory viruses in diabetic patients.J Infect Public Health. 2022 Apr;15(4):412-424. doi: 10.1016/j.jiph.2022.03.002. Epub 2022 Mar 9. J Infect Public Health. 2022. PMID: 35339014 Review.
Cited by
-
[Vaccination in old age: an overview].Z Gerontol Geriatr. 2023 Dec;56(8):679-687. doi: 10.1007/s00391-023-02265-1. Epub 2023 Dec 5. Z Gerontol Geriatr. 2023. PMID: 38051357 German.
-
Understanding the Barriers and Attitudes toward Influenza Vaccine Uptake in the Adult General Population: A Rapid Review.Vaccines (Basel). 2023 Jan 13;11(1):180. doi: 10.3390/vaccines11010180. Vaccines (Basel). 2023. PMID: 36680024 Free PMC article. Review.
-
Hyperactivity of the CD155 immune checkpoint suppresses anti-viral immunity in patients with coronary artery disease.Nat Cardiovasc Res. 2022 Jul;1(7):634-648. doi: 10.1038/s44161-022-00096-8. Epub 2022 Jul 13. Nat Cardiovasc Res. 2022. PMID: 36860353 Free PMC article.
-
[Validity and usefulness of the RAE-CMBD studying patients hospitalised with influenza].Rev Esp Quimioter. 2023 Apr;36(2):160-168. doi: 10.37201/req/074.2022. Epub 2023 Jan 18. Rev Esp Quimioter. 2023. PMID: 36651282 Free PMC article. Spanish.
-
[Enhanced targeted influenza vaccines - New evidence shows higher effectiveness in older adults].Dtsch Med Wochenschr. 2023 Apr;148(9):556-562. doi: 10.1055/a-2032-1368. Epub 2023 Mar 29. Dtsch Med Wochenschr. 2023. PMID: 36990440 Free PMC article. German.
References
-
- World Health Organization. Influenza (Seasonal). 2018; Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Accessed: 17 July 2019.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical